Melinta therapeutics, inc. /new/ (MLNT)
Income statement / Quarterly
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Revenue
Total revenue

15,870

15,955

14,084

35,489

34,078

12,022

14,841

-

3,191

3,979

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract research

-

-

-

-

-

-

-

-

-

-

2,558

3,606

3,972

3,420

2,679

4,704

2,497

3,171

2,076

1,298

3,431

1,896

2,984

2,073

1,172

232

0

-

-

-

-

-

-

-

-

License

-

-

-

-

-

-

-

-

-

-

19,905

4,339

-

-

-

-

0

0

10,000

3

4,335

-

-

-

-

4,335

-

-

-

-

-

-

-

-

-

Supply

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,090

0

1,883

1,887

1,169

0

0

99

-

-

-

-

-

-

-

-

-

-

-

-

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Total revenue

-

-

-

-

-

-

-

-

-

-

22,463

7,945

3,972

3,420

2,679

5,794

2,497

5,054

13,963

2,470

7,766

1,896

3,083

2,073

1,172

4,567

0

-

-

-

-

-

-

-

-

Operating expenses:
Cost of goods sold

8,213

8,639

7,365

8,989

13,393

10,989

7,686

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

4,696

3,527

5,364

10,402

13,065

15,813

16,129

11,599

10,884

14,075

12,917

21,043

21,096

16,018

23,529

20,018

23,541

23,676

26,118

15,305

15,653

15,197

16,383

15,683

11,919

6,327

7,370

4,413

3,156

7,423

1,876

1,458

6,661

4,361

4,392

Impairment of Intangible Assets, Finite-lived

176,725

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

26,417

30,932

25,941

29,455

34,287

34,946

34,624

37,349

10,304

7,699

7,973

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

-

-

-

-

-

-

-

-

-

-

-

18,205

15,021

11,988

8,324

6,641

5,848

5,732

4,650

3,429

2,853

2,604

3,190

2,538

2,167

2,081

2,647

1,825

1,494

1,777

972

1,057

965

806

880

Total operating expenses

216,051

43,098

38,670

73,934

60,745

61,748

58,439

48,948

21,188

21,774

20,890

-26,775

36,117

28,006

31,853

-

29,389

-

-

-

-

17,802

-

18,219

14,086

8,408

10,018

-

4,650

9,201

-

-

-

-

-

Loss from operations

-200,181

-27,143

-24,586

-38,445

-26,667

-49,726

-43,598

-44,717

-17,997

-17,795

1,573

-31,303

-32,145

-24,586

-29,174

-20,865

-26,892

-24,354

-16,805

-16,264

-10,740

-15,906

-16,490

-16,148

-12,914

-3,841

-10,018

6,238

-4,650

-9,201

-2,848

2,515

7,626

5,167

5,272

Other income (expense):
Interest income

411

210

187

209

248

63

210

131

7

12

5

145

128

104

98

5

0

2

2

1

1

88

45

2

3

12

0

1

0

0

105

80

1

0

1

Interest expense

6,853

8,176

7,103

10,847

11,477

10,659

10,196

-2,157

2,381

1,762

1,622

280

295

323

330

296

679

617

614

632

617

559

576

684

736

384

327

331

330

327

407

432

291

0

0

Interest expense (related party, see Note 4)

1,403

1,365

564

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)

-

261

-

-

-

2,389

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair Value Adjustment of Warrants

-

-

-6,015

-

-

-

-24,085

0

-701

311

55

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain (Loss) on Extinguishment of Debt

-2,692

0

-346

0

0

0

-2,595

-

0

-607

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense)

-147

8

-73

-

62

32

4

-

34

37

25

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain (Loss) on Contract Termination

0

-

-

-

5,330

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss On Write-Down Of Debt

7,609

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grant income (expense)

943

25

-62

-

472

2,121

2,658

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

0

0

0

Other income (expense), net

-13,201

-9,037

-1,946

-5,675

-1,193

-6,054

14,166

25,937

-1,639

-2,631

-1,647

-4,113

-167

-219

-232

-

-679

-

-

-

-

-471

-

-682

-733

-372

-326

-

-330

-326

-

-

-

-

-

Net Income (Loss) Attributable to Parent

-213,382

-36,180

-26,532

-44,120

-27,860

-55,780

-29,432

-18,780

-19,636

-20,426

-74

-31,438

-32,312

-24,805

-29,406

-21,156

-27,571

-24,969

-17,417

-

-

-16,377

-

-16,829

-13,647

-4,213

-10,344

-

-

-

-3,150

-

-

-

-

Accretion of convertible preferred stock dividends

-

-

-

-

-

-

-

2,098

5,720

5,721

5,720

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss and comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,568

-4,981

-9,527

-

2,867

7,916

5,167

5,271

Accretion of redeemable convertible preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-0

314

941

941

940

941

Net loss available to common shareholders

-

-

-

-

-

-

-

-20,878

-25,356

-26,147

-5,794

-

-

-

-

-

-

-

-

-

-

-

-

-16,830

-

-4,213

-

6,568

-4,981

-9,527

-3,464

3,808

8,857

6,107

6,212

Basic and diluted net loss per share (in usd per share)

-15.67

-3.07

-2.34

-2.95

-2.49

-6.92

-4.76

1,840.32

-857.35

-884.09

-208.16

-0.60

-0.62

-0.51

-0.61

-0.48

-0.63

-0.57

-0.41

-0.46

-0.34

-0.49

-0.51

-0.51

-0.41

-0.16

-0.42

-0.27

-0.24

-0.45

-0.26

-7.13

-16.59

-11.65

-12.16

Basic and diluted weighted average shares outstanding (in shares)

13,614

11,801

11,330

11,281

11,202

8,059

6,183

2,774

29

29

27

52,389

52,072

48,897

47,853

43,976

43,910

43,686

42,671

36,493

33,588

33,216

33,201

33,197

33,184

26,382

24,903

24,147

21,038

21,034

13,251

534

534

524

511

Product sales, net
Total revenue

15,770

13,825

11,775

14,554

11,028

9,152

11,846

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract research
Total revenue

100

2,130

1,409

2,776

3,036

2,870

2,995

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License
Total revenue

0

0

900

18,159

20,014

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common Stock Warrants And Conversion Right
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)

4,149

-

-

-

4,172

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-